Australia's Invion jumps on partnership over wart virus treatment
23/02/2024 01:02
** Shares of Invion IVX.AX rise as much as 25% to A$0.005,
posting their biggest intraday pct gain since Jan. 20
** Life sciences co signs collaboration agreement with South
Korean firm Dr.inB to develop PhotosoftTM technology for the
treatment of Human Papoloma Virus (HPV), which causes warts on
body
** PhotosoftTM technology uses non-toxic photosensitisers
and visible light in combination and is used for the treatment
of a range of cancers, atherosclerosis and infectious diseases
** About 1.7 mln shares change hands, 2.5x the 30-day avg
volumes
** Stock down 20% YTD
(Reporting by Neha Soni in Bengaluru)
((Neha.Soni@thomsonreuters.com))
Recent news on Invion
See all newsAustralia's Invion rises after securing clinical trial funding arrangements
Brief: Invion Ltd Says Funding Agreements Cover Up To 85% Of Clinical Trials Costs
Brief: Invion Announces Preclinical Research Collaboration With Percheron Therapeutics
Australia's Invion enters ophthalmology agreement with Sangmyung Innovation
Brief: Invion Signs First Ophthalmology Collaboration Agreement With Sangmyung Innovation